[go: up one dir, main page]

AU2001278981A1 - Prevention and treatment of sexual arousal disorders - Google Patents

Prevention and treatment of sexual arousal disorders

Info

Publication number
AU2001278981A1
AU2001278981A1 AU2001278981A AU7898101A AU2001278981A1 AU 2001278981 A1 AU2001278981 A1 AU 2001278981A1 AU 2001278981 A AU2001278981 A AU 2001278981A AU 7898101 A AU7898101 A AU 7898101A AU 2001278981 A1 AU2001278981 A1 AU 2001278981A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
sexual arousal
arousal disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278981A
Inventor
Yuet W. Kan
Ching-Shwun Lin
Tom F Lue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001278981A1 publication Critical patent/AU2001278981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001278981A 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders Abandoned AU2001278981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22003100P 2000-07-21 2000-07-21
US60/220,031 2000-07-21
PCT/US2001/022970 WO2002007757A2 (en) 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders

Publications (1)

Publication Number Publication Date
AU2001278981A1 true AU2001278981A1 (en) 2002-02-05

Family

ID=22821763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278981A Abandoned AU2001278981A1 (en) 2000-07-21 2001-07-19 Prevention and treatment of sexual arousal disorders

Country Status (4)

Country Link
US (2) US6852323B2 (en)
EP (1) EP1365794A2 (en)
AU (1) AU2001278981A1 (en)
WO (1) WO2002007757A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223957A4 (en) * 1999-10-01 2003-05-14 Univ Duke METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
JP2012530701A (en) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド Treatment of multiple sclerosis with laquinimod
KR20160148050A (en) * 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 Treatment of crohn's disease with laquinimod
ES2731052T3 (en) * 2009-08-10 2019-11-13 Active Biotech Ab Treatment of Huntington's disease using laquinimod
CA2791709A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
ES2601819T3 (en) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
KR20150135552A (en) * 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 Treatment of lupus nephritis using laquinimod
JP2014530821A (en) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド Treatment of multiple sclerosis combining laquinimod and fingolimod
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammation with laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
CA2973096A1 (en) 2015-01-06 2016-07-14 Cardiovascular Biotherapeutics, Inc. Angiogenic treatment of ischemic heart disease
EP3259012A4 (en) 2015-02-16 2018-09-19 CardioVascular BioTherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
GB202003109D0 (en) * 2020-03-04 2020-04-15 Univ Bristol Gene therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US5026839A (en) 1985-12-17 1991-06-25 Synergen, Inc DNA encoding a basic fibroblast growth factor
SE463851B (en) 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
US5188943A (en) 1988-11-07 1993-02-23 Synergen, Inc. Method of producing high molecular weight human fibroblast growth factors
US5130418A (en) 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5270053A (en) 1990-04-03 1993-12-14 Ciba-Geigy Corp. Parenterally administerable liposome formulation comprising synthetic lipid
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5235043A (en) 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
ES2093112T3 (en) 1990-09-25 1996-12-16 Genentech Inc NEW NEUROTROPHIC FACTOR.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5206354A (en) 1990-11-23 1993-04-27 American Cyanamid Company Dna sequence encoding active fragment of fibroblast growth factor, hbf-2
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
DE4221256C2 (en) 1992-06-26 1997-07-10 Lancaster Group Ag Galenic composition for topical use
US5646181A (en) 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
JPH06247842A (en) 1993-02-23 1994-09-06 Green Cross Corp:The Production of liposome composition
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
CA2188385C (en) 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
AU5557796A (en) 1995-04-18 1996-11-07 Dehlinger, Peter J. Liposome drug-loading method and composition
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
SI1445322T2 (en) 1995-06-15 2012-10-30 Crucell Holland Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2227193A1 (en) 1995-07-17 1997-02-06 Xiaomei Jin P16 expression constructs and their application in cancer therapy
JP2000502682A (en) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド Local intravascular delivery of growth factors that promote angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
WO1997035560A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved echogenic liposome compositions
JPH10212241A (en) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Formulation containing BDNF stably
US6133026A (en) 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
DK1017365T3 (en) 1997-06-23 2004-03-29 Alza Corp Liposome enclosed polynucleotide composition and method
US6221646B1 (en) 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
SE9703226D0 (en) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6706682B2 (en) 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
FI991197A0 (en) 1999-05-27 1999-05-27 Mart Saarma Neurotropic factors in the treatment of pelvic peripheral dysfunction
US6436944B1 (en) * 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
EP1223957A4 (en) 1999-10-01 2003-05-14 Univ Duke METHOD FOR TREATING ERECTILE DYSFUNCTION
US20020032153A1 (en) * 2000-03-10 2002-03-14 Whitehouse Martha Jo Methods and compositions for the treatment and prevention of erectile dysfunction

Also Published As

Publication number Publication date
US6852323B2 (en) 2005-02-08
EP1365794A2 (en) 2003-12-03
US7485311B2 (en) 2009-02-03
WO2002007757A2 (en) 2002-01-31
WO2002007757A3 (en) 2003-09-18
US20020160951A1 (en) 2002-10-31
US20040180830A1 (en) 2004-09-16
WO2002007757A9 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A3 (en) Prevention and treatment of amyloidogenic disease
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001278981A1 (en) Prevention and treatment of sexual arousal disorders
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU7601400A (en) Treatment and prevention of hepatic disorders
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2002340465A1 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
AU2001269785A1 (en) Method of treatment of obesity and paralyzed muscle and ergogenic aids
AU2002228652A1 (en) Treatment of disorders using polyethylenimine diazeniumdiolate
GB2360453B (en) Treatment of skin conditions
PL362980A1 (en) Treatment of sexual dysfunction
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
IL152782A0 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
IL142102A0 (en) Zinc-sensing receptor and methods of treatment of disorders associated herewith
AU2001239005A1 (en) Treatment and/or prevention of ocular pain